Who We Are
ADePT was formed in 2020 as a joint project between Greater Manchester Mental Health (GMMH) and the metacognitive therapy research group led by Professor Wells at the University of Manchester.
The Anxiety, Depression and Psychological Therapies Research Unit (ADePT-RU) conducts cutting edge evidenced based research aiming to improve our understanding and treatment of mental health disorders in adults and children. Currently our research is testing treatments for anxiety and depression in patients with cardiovascular disease, and treating anxiety and depression in burns and plastic surgery patients, evaluating home-based therapies, and transdiagnostic group therapy approaches in adults and young people.
To make our research happen we work with a range of leading academic and clinical partners along with patients and members of the public to ensure our research is in line with patient’s needs and provides direct patient benefits.
MCT is a novel, evidence-based treatment approach with an explicit focus on metacognition, defined as “cognition applied to cognition” – MCT functions at the meta-level, in which thoughts are unimportant but the way an individual responds to and regulates their thoughts is considered crucial for the cause and maintenance of the psychological disorder.
OUR KEY AIMS
Our Treatment Approaches
How is MCT different to other types of therapy?
What is MCT
Metacognitive therapy (MCT) is a recent treatment that is proving to be highly effective for a range of anxiety disorders and depression. A special issue in the Journal Frontiers in Psychology presents recent research in MCT by members of ADePT and our international collaborators. The special issue brings together 100 academics and clinicians from across the world contributing to 31 articles and has been viewed over 300, 000 times.